+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Efficacy and tolerability of a new opioid analgesic formulation, buprenorphine transdermal therapeutic system (TDS), in the treatment of patients with chronic pain. A randomised, double-blind, placebo-controlled study



Efficacy and tolerability of a new opioid analgesic formulation, buprenorphine transdermal therapeutic system (TDS), in the treatment of patients with chronic pain. A randomised, double-blind, placebo-controlled study



Pain Clinic 15(2): 193-202



This randomised, double-blind, placebo-controlled study evaluated the efficacy and tolerability of buprenorphine TDS, a new transdermal formulation of the opioid analgesic buprenorphine.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 010569392

Download citation: RISBibTeXText

DOI: 10.1163/156856903321579334


Related references

Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: A multicenter, randomized, double-blind, placebo-controlled trial. Clinical Therapeutics 25(1): 150-168, 2003

Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-naïve patients with moderate to severe chronic low back pain: an enriched, randomized, double-blind, placebo-controlled study. Journal of Pain and Symptom Management 42(6): 903-917, 2011

Efficacy and Safety of the Seven-Day Buprenorphine Transdermal System in Opioid-Naive Patients with Moderate to Severe Chronic Low Back Pain An Enriched, Randomized, Double-Blind, Placebo-Controlled Study. 2011

A randomized, double-blind, double-dummy comparison of the efficacy and tolerability of low-dose transdermal buprenorphine (BuTrans seven-day patches) with buprenorphine sublingual tablets (Temgesic) in patients with osteoarthritis pain. Journal of Pain and Symptom Management 40(2): 266-278, 2010

A Randomized, Double-Blind, Double-Dummy Comparison of the Efficacy and Tolerability of Low-Dose Transdermal Buprenorphine (BuTrans Seven-Day Patches) With Buprenorphine Sublingual Tablets (Temgesic) in Patients With Osteoarthritis Pain. Yearbook of Anesthesiology and Pain Management 2011: 350-351, 2011

Intravenous nonopioid analgesic drugs in chronic low back pain patients on chronic opioid treatment: a crossover, randomised, double-blinded, placebo-controlled study. European Journal of Anaesthesiology 31(1): 35-40, 2014

Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. Clinical Therapeutics 26(11): 1808-1820, 2004

Intravenous nonopioid analgesic drugs in chronic low back pain patients on chronic opioid treatment: A crossover, randomised, double-blinded, placebo-controlled study: Retraction. European Journal of Anaesthesiology 32(4): 287-287, 2015

Buprenorphine transdermal system in adults with chronic low back pain: a randomized, double-blind, placebo-controlled crossover study, followed by an open-label extension phase. Clinical Therapeutics 32(5): 844-860, 2010

A double-blind, placebo-controlled study of the tolerability and efficacy of a new kappa-opioid receptor agonist (R-84760) in patients with pain after dental surgery. Clinical Drug Investigation 20(6): 409-414, 2000

A 6-months, randomised, placebo-controlled evaluation of efficacy and tolerability of a low-dose 7-day buprenorphine transdermal patch in osteoarthritis patients naïve to potent opioids. Scandinavian Journal of Pain 1(3): 122-141, 2010

Efficacy and Safety of Analgesic Treatment for Depression in People with Advanced Dementia: Randomised, Multicentre, Double-Blind, Placebo-Controlled Trial (DEP.PAIN.DEM). Drugs and Aging 35(6): 545-558, 2018

Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet. Neurology 14(11): 1091-1100, 2015

Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 393(10173): 778-790, 2019

A Phase 2b, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Noncancer Pain. Pain Medicine 18(12): 2350-2360, 2017